局灶节段性肾小球硬化的治疗进展

Advances in the research of treatment of focal segmental glomerulosclerosis

局灶节段性肾小球硬化(FSGS)临床上主要表现为不同程度的蛋白尿,可伴镜下血尿、高血压或肾小管功能受损,且易并发感染、深静脉血栓等并发症。本病预后较差,个体间治疗效果存在较大差异,糖皮质激素是目前治疗FSGS的主要药物,部分患者疗效较好,但仍冇部分患者存在激素抵抗,肾功能迅速恶化。因此,近年来人们开始探索研究各种新型药物用于难治性FSGS的治疗,并取得-定疗效,本文对FSGS的治疗进展进行综述。

Focal segmental glomerulosclerosis (FSGS) is clinically characterized by proteinuria of varying degrees, which can be accompanied by hematuria, hypertension or impaired renal tubular function, and is prone to complications such as infection and deep venous thrombosis.The prognosis of this disease is poor, and there are great differences in the therapeutic effect between individuals.Glucocorticoid is the main drug for FSGS at present.Some patients have better curative effect, but there are still some patients with hormone resistance and rapid deterioration of renal function.Therefore ,in recent years, people began to explore and study various new drugs for the treatment of refractory FSGS, and achieved a certain effect.This article reviews the advances in the research of treatment of FSGS.